HC Wainwright Reaffirms Buy Rating for Talphera (NASDAQ:TLPH)

Talphera (NASDAQ:TLPH)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $6.00 target price on the stock.

Separately, Maxim Group raised shares of Talphera to a “strong-buy” rating in a report on Friday, November 8th.

Talphera Stock Up 13.4 %

Shares of Talphera stock opened at $0.71 on Tuesday. Talphera has a 12-month low of $0.50 and a 12-month high of $1.61. The stock has a market capitalization of $12.17 million, a P/E ratio of -1.04 and a beta of 0.28. The company has a 50-day simple moving average of $0.65 and a 200 day simple moving average of $0.82.

Institutional Trading of Talphera

An institutional investor recently bought a new position in Talphera stock. Nantahala Capital Management LLC purchased a new position in shares of Talphera, Inc. (NASDAQ:TLPH) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 1,992,519 shares of the company’s stock, valued at approximately $1,773,000. Nantahala Capital Management LLC owned approximately 11.73% of Talphera as of its most recent SEC filing. Institutional investors and hedge funds own 37.67% of the company’s stock.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.